Study on the relationship between Glasgow prognostic score and nutritional， physical status in patients with gastric cancer
GE Shao-hua， CHEN Xing-yun， ZHANG Hai-yang， NING Tao， LI Hong-li， BA Yi
Tianjin Medical University Cancer Institute and Hospital， National Clinical Research Center for Cancer， Tianjin’s Clinical Research Center for Cancer， Key Laboratory of Cancer Prevention and Therapy， Tianjin Medical University， Tianjin 300060， China
Abstract To observe the value of Glasgow prognostic score (GPS) based on systemic inflammatory response in evaluating nutritional status and performance status in patients with gastric cancer. Methods 43 patients with gastric cancer hospitalized in our hospital from January 2013 to March 2014 with body composition measurement and hematological data were collected. The relationship between GPS score and nutritional， performance status were analyzed. Results In 43 gastric cancer patients， there were 18 males and 25 females. There were 27， 14 and 2 patients with GPS scores of 0， 1 and 2， respectively. It was found there was no significant statistical relationship between GPS score with NRS 2002 (nutrition risk screening， NRS 2002) score and PG-SGA (patient-generated subjective global assessment) score. The serum level of prealbumin in patients with GPS score ≥1 was significantly lower than that of patients with GPS score 0 (P=0.048)， and there was a trend to decline in blood lymphocyte count (P=0.078). The KPS score of patients with GPS score ≥ 1 was lower (P=0.015)， and there was a trend of correlation between GPS and quality of life (P=0.076). In analysis involving body composition measurement， the mid-upper arm circumference in patients with GPS score ≥1 turned to be significantly smaller than that of GPS score 0 (P=0.042). The maximum circumferences of both legs were also obviously smaller in patients with GPS ≥1 than that of GPS 0. The upper arm muscle circumference， triceps skin fold thickness and non-dominant hand grip strength were all reduced， but no significant statistical difference was found between patients with GPS ≥1 and GPS 0. Conclusion GPS score is based on systemic inflammatory response and related to parts of nutritional indicators and performance status of gastric cancer patients. It is a promising simplified alternative index for nutritional and performance status assessment of gastric cancer patients.
GE Shao-hua,CHEN Xing-yun,ZHANG Hai-yang, et al. Study on the relationship between Glasgow prognostic score and nutritional， physical status in patients with gastric cancer[J]. Electron J Metab Nutr Cancer, 2019, 6(2): 212-215.
1.黄道来，吴向华，陈俊强，等. NRS 2002、PG-SGA、BMI、TF 在胃癌营养筛查与评估中的作用.肿瘤代谢与营养电子杂志.2017；4(3):317-321.
2.Ryu SW， Kim IH. Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol. 2010；16(26):3310-3317.
3.Fukuda Y， Yamamoto K， Hirao M， et al.Prevalence of malnutrition among gastric cancer patients undergoing gastrectomy and optimal preoperative nutritional support for preventing surgical site infections.Ann Surg Oncol. 2015；22 Suppl 3:S778-785.
4.Zablocka-Slowinska KA， Kosacka M， Porebska I， et al.The usefulness of routinely used malnutrition screening tools in predicting anemia in lung cancer patients. Adv Clin Exp Med. 2017；26(9):1383-1389.
5.Fujiya K， Kawamura T， Omae K， et al.Impact of malnutrition after gastrectomy for gastric cancer on long-term survival.Ann Surg Oncol. 2018；25(4):974-983.
6.Zhang CX， Wang SY， Chen SQ， et al.Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features:a meta-analysis. Onco Targets Ther. 2016；9:3883-3891.
7.Forrest LM， McMillan DC， McArdle CS， et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.Br J Cancer. 2003；89(6):1028-1030.
8.Roncolato FT， Berton-Rigaud D， O’Connell R， et al. Validation of the modified Glasgow prognostic score (mGPS) in recurrent ovarian cancer (ROC) - analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).Gynecol Oncol. 2018；148(1):36-41.
9.Okano N， Kasuga A， Kawai K， et al. The modified Glasgow prognostic score in patients with gemcitabine-refractory biliary tract cancer. Anticancer Res. 2018；38(3):1755-1761.
10.Jin J， Hu K， Zhou Y， et al. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies.Int J Biol Markers. 2018；33(2):201-207.
11.Minami S， Ogata Y， Ihara S， et al. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer. Lung Cancer (Auckl). 2017；8:249-257.
12.Liu Y， He X， Pan J， et al. Prognostic role of Glasgow prognostic score in patients with colorectal cancer: evidence from population studies. Sci Rep. 2017；7(1):6144.
13.McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013；39(5):534-540.
14.Zhu J， Wang H， Liu CC， et al. The Glasgow prognostic score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer Res Clin Oncol. 2016；142(11):2339-2345.
15.Yuan SQ， Nie RC， Chen YM， et al. Glasgow prognostic score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding. Oncol Lett. 2018；15(4):4193-4200.
16.Zou Z， Zhao L， Su S， et al. The plasma levels of 12 cytokines and growth factors in patients with gastric cancer. Medicine (Baltimore). 2018；97(19):e0413.
17.Mauricio SF， da Silva JB， Bering T， et al. Relationship between nutritional status and the Glasgow prognostic score in patients with colorectal cancer. Nutrition. 2013；29(4):625-629.
18.Matsunaga T， Miyata H， Sugimura K， et al. Prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer. Anticancer Res. 2019；39(1):449-458.
19.余静，周福祥.肌肉减少症与代谢综合征关系的研究进展. 肿瘤代谢与营养电子杂志. 2018；5(3):324-327.
20.Feliciano EMC， Kroenke CH， Meyerhardt JA， et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol. 2017；3(12):e172319.
